T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. ET and will be available on Harpoon’s website following the presentation.įor more details about the ASH Annual Meeting please visit.
The posters will be available for viewing on Decemat 9 a.m. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I Title: The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma Location: Georgia World Congress Center, Hall B5 Poster Presentation Date and Time: Saturday, Decem5:30 p.m. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I Title: An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma The meeting will be held virtually and in person in Atlanta, Ga.
(NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. 04, 2021 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc.
0 kommentar(er)
